Latest
Our Pick PPHM, skyrocketed, holy cow up 80% Today! See with you own eyes!
PPHM, Peregrine Pharma, up a whopping 80% in one day, you could have almost doubled your money in just a week.
YOU COULD HAVE ALMOST DOUBLED YOUR MONEY!
NOT in 1 year, Not in Six Months, ONE WEEK folks!
On New Year's Eve (see the list) we published our Top 10 List, PPHM on that day gained 7%, today it gained a whopping 80%, we think this stock has legs! You want to keep a close eye on this and on our other picks!
You can't afford to miss opportunities like these, can you?
Check out Today's Top 10 Picks now!
Get the Fresh, FREE, Sun Dried, Nutrient Rich, Piping Hot Picks Everyday!
Sign-up its FREE!
High Octane Solar and Alternative Energy stocks! Top 10 Picks
Fiscal Cliff brought much needed sunshine to Solar Stocks. Renewable energy stocks across the board got a huge boost from the extension of credits and R&D expenditure. You could have doubled your money in a matter of weeks, see our Solar picks.
Stay ahead, stay informed sign-up and make money, its FREE
Today's Top Picks
SONS, CIS, ZLCS, IDRA, BGMD, CSUN, CYTK, QUIK, CRDC, CSIQ
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Stock to Watch, Emgold Mining, EMR.V, EGMCF.PK
Stock to Watch!
Emgold Mining Corp. EMR (TSX.V) EGMCF (OTCQB)
Emgold Mining Corporation is a gold exploration and development company with five exploration and development projects in North America. The Company is focused on acquiring and developing quality properties, and advancing them through exploration, permitting, construction, and ultimately create a new gold producing company.
Focus
The Company is focused on reopening the historic Idaho-Maryland Gold Mine located in Grass Valley, California. The Company plans to develop a 2,400 ton per day mining operation with potential to produce over 200,000 ounces of gold per year.
Additional Properties
Emgold Mining also has a portfolio of four early to middle stage mineral exploration projects including the Buckskin-Rawhide Property, and the Koegel Rawhide Property in Nevada, the Stewart Property, and the Rozan Property in British Columbia.
INVESTMENT HIGHLIGHTS
-
Opportunity to invest in a world class gold asset whose main property has potential to develop a 3-5 million ounce gold resource.
-
Idaho-Maryland Project in California has significant gold resources and production potential
-
Measured & Indicated: 472,000 ounces of gold. Inferred: 1,002,000 ounces of gold.
-
Company planning to produce over 200,000 ounces of gold annually.
-
13 million ounces of gold was produced within 3 mile radius, see why Emgold's has been involved with this property since 1993!
-
-
Four additional excellent exploration properties in Nevada and British Columbia. Learn more about these great properties.
-
The Company’s gold assets and solid resource base seems to be currently undervalued with the stock trading at $0.10 per share, implied value per ounce of only $4 per ounce of gold. See the Valuation
-
The Company successfully raised $2.2 million and planning to raise additional funds to advance Idaho-Maryland project.
-
Strong management team and Board of Directors with considerable exploration and development experience. meet the Management Team!
-
Find out the 'Target Price', read the compelling analysis.
-
Full Report is now available for FREE! download now.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company or a third party. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
Marina Biotech, MRNA, Summary, Profile
Marina Biotech | MRNA | Summary | Profile
Marina Biotech – MRNA - is focused on the discovery and development of novel RNAi-based therapeutics in the area of oncology, bladder and liver cancer.
The company is exploring the potential of RNAi-based therapeutics through the development of multiple broad-based, state-of-the-art drug discovery platforms built upon industry leading expertise in RNA chemistry, microbiology and oligonucleotide delivery.
Bladder Cancer
Marina Biotech is conducting preclinical studies in bladder cancer utilizing our tauRNAi platform. Bladder cancer ranks as the 4th most common cancer in men, and the 9th leading cause of death in men in the US. Approximately 75% of all bladder cancer cases in the US are in men. In the US, it is currently estimated that on a yearly basis, more than 70,000 new patients will be diagnosed with bladder cancer and approximately 15,000 deaths will occur from bladder cancer.
Liver Cancer
Marina Biotech is utilizing the tauRNAi platform in preclinical studies of hepatocellular carcinoma, more commonly known as liver cancer. Leading causes of liver cancer include viral infection (hepatitis), toxins, and damage to the liver that result in cirrhosis. Worldwide there are more than 500,000 new cases of liver cancer each year. It is currently estimated that in the US, more than 20,000 new cases of liver cancer will be diagnosed and 19,000 deaths are expected to occur due to liver cancer.
The company has partnered with World's leading companies and universities, including University of Michigan and University of Helsinki. The partners include Roche and Novartis.
The stock is trading near 52WK LOWS, may bounce back keep an eye!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
OTCKing
Feed Entries
